title: Cutaneous leishmaniasis in a patient receiving infliximab for psoriatic arthritis: treatment with cryotherapy and intralesional meglumine antimonate.
authors.affiliation: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. Electronic address: acatala@santpau.cat.
authors.forename: A
authors.initials: A
authors.lastname: Català
authors.affiliation: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: M A
authors.initials: MA
authors.lastname: Barnadas
authors.affiliation: Servicio de Microbiología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: C
authors.initials: C
authors.lastname: Muñoz
authors.affiliation: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: L
authors.initials: L
authors.lastname: Puig
mesh_terms: D000328:Adult; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D003131:Combined Modality Therapy; D017679:Cryotherapy; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects* / Q000627:therapeutic use; D015552:Injections, Intralesional; D016773:Leishmaniasis, Cutaneous / Q000139:chemically induced / Q000628:therapy*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000008:administration & dosage*
chemical_list: D000981:Antiprotozoal Agents; D018501:Antirheumatic Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000069285:Infliximab